Pharming Group (NASDAQ:PHAR) Sees Strong Trading Volume – Here’s What Happened

Posted by Caroline Horne on Jun 17th, 2025

Shares of Pharming Group (NASDAQ:PHAR – Get Free Report) saw unusually-strong trading volume on Tuesday . Approximately 5,054 shares traded hands during trading, a decline of 19% from the previous session’s volume of 6,208 shares.The stock last traded at $11.20 and had previously closed at $10.75.

Wall Street Analysts Forecast Growth

Several analysts recently commented on the company. HC Wainwright reaffirmed a “buy” rating and issued a $37.00 price objective on shares of Pharming Group in a report on Thursday, March 20th. Oppenheimer upped their price target on shares of Pharming Group from $30.00 to $39.00 and gave the stock an “outperform” rating in a research report on Friday, March 14th.

Get Our Latest Stock Report on Pharming Group

Pharming Group Trading Down 1.9%

The company has a debt-to-equity ratio of 0.41, a current ratio of 3.53 and a quick ratio of 2.76. The business’s 50 day simple moving average is $9.70 and its 200 day simple moving average is $9.20. The company has a market capitalization of $755.82 million, a price-to-earnings ratio of -42.73 and a beta of 0.02.

Pharming Group (NASDAQ:PHAR – Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported ($0.22) EPS for the quarter, beating the consensus estimate of ($0.25) by $0.03. The company had revenue of $79.09 million for the quarter, compared to analyst estimates of $67.74 million. Pharming Group had a negative return on equity of 7.65% and a negative net margin of 6.09%. Research analysts anticipate that Pharming Group will post -0.2 EPS for the current year.

Pharming Group Company Profile

(Get Free Report)

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.